Patents by Inventor Morten Asser Karsdal
Morten Asser Karsdal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240125802Abstract: A method of immunoassay for detecting and/or monitoring esophageal fibrosis and/or dysphagia in a patient and/or assessing the likelihood of or the severity of esophageal fibrosis and/or dysphagia in a patient by contacting a biofluid sample from a patient with a monoclonal antibody that specifically binds to a C-terminal epitope of the C5 domain of the ?3 chain of type VI collagen.Type: ApplicationFiled: February 17, 2022Publication date: April 18, 2024Applicant: Nordic Bioscience A/SInventors: Joachim Høg Mortensen, Martin Pehrsson, Morten Asser Karsdal
-
Publication number: 20240085428Abstract: Disclosed herein are monoclonal antibodies that specifically recognise and bind to a C-terminus of a peptide that is the C-terminus neo-epitope formed on cleavage of the N-terminal pro-peptide of the ?1-chain of type XI collagen at A?511?, and immunoassay methods and kits using and containing the antibodies. The immunoassay methods may be used for detecting and/or monitoring and/or assessing the severity or prognosis of diseases, such as, but not limited to, cancer.Type: ApplicationFiled: December 20, 2021Publication date: March 14, 2024Applicant: Nordic Bioscience A/SInventors: Nicholas Willumsen, Neel Ingemann Nissen, Morten Asser Karsdal
-
Publication number: 20240003906Abstract: The present invention relates to a sandwich immunoassay and kits for detecting in a biological sample cross-linked CTX-III, and its use in evaluating the efficacy of drugs targeting lysyl oxidases (LOXs). Cross-linked CTX-III can be used as a biomarker in diseases associated with fibrosis, including liver fibrosis, chronic intestinal disease, eosinophilic esophagitis and cancer.Type: ApplicationFiled: April 15, 2020Publication date: January 4, 2024Applicant: Nordic Bioscience A/SInventors: Martin Pehrsson, Morten Asser Karsdal, Diana Julie Leeming, Mette Juul Fisker, Tina Manon-Jensen, Joachim Høg Mortensen
-
Publication number: 20230358752Abstract: Described herein are immunoassay methods for detecting and/or monitoring a cancer in a patient by contacting a biofluid sample from a patient with a monoclonal antibody that specifically binds to a C-terminal epitope of type XXVIII collagen, and detecting and determining the amount of binding between the monoclonal antibody and peptides in the sample.Type: ApplicationFiled: September 10, 2021Publication date: November 9, 2023Applicant: Nordic Bioscience A/SInventors: Federica Genovese, Nicholas Willumsen, Alexander Lynge Reese-Petersen, Shu Sun, Morten Asser Karsdal
-
Publication number: 20230280350Abstract: The present invention relates to a type XVI collagen assay and its use in evaluating diseases associated with type XVI collagen, in particular colorectal cancer and ulcerative colitis, and for identifying a subgroup of patients with Crohn’s disease that have (or are likely to develop) fibrostenotic strictures.Type: ApplicationFiled: April 17, 2023Publication date: September 7, 2023Applicant: Nordic Bioscience A/SInventors: Christina Jensen, Joachim Hog Mortensen, Nicholas Willumsen, Morten Asser Karsdal
-
Publication number: 20230184787Abstract: Disclosed herein are immunoassay methods for detecting and quantifying human neutrophil elastase (HNE) generated fragments of calprotectin in a biofluid sample; and monoclonal antibodies and assay kits for use in such methods. The methods may be used for detecting, monitoring and/or determining the status or severity of a disease characterized by or exhibiting inflammation in a patient.Type: ApplicationFiled: May 12, 2021Publication date: June 15, 2023Applicant: Nordic Bioscience A/SInventors: Joachim Høg Mortensen, Dovile Sinkeviciute, Tina Manon-Jensen, Morten Asser Karsdal, Anne-Christine Bay-Jensen, Signe Holm Nielsen, Annika Hummersgaard Hansen, Jannie Marie Bülow Sand, Diana Julie Leeming, Nicholas Willumsen, Christina Jensen
-
Publication number: 20220380432Abstract: Disclosed herein are calcitonin mimetics that are acylated at a lysine residue located at the 11 position or 19 position of the calcitonin mimetic, and the use thereof as medicaments in the treatment of various diseases and disorders, including diabetes, excess bodyweight, excessive food consumption and metabolic syndrome, NASH, alcoholic and non-alcoholic fatty liver disease, the regulation of blood glucose levels, the regulation of response to glucose tolerance tests, the regulation of food intake, and the treatment of osteoporosis and the treatment of osteoarthritis.Type: ApplicationFiled: August 22, 2019Publication date: December 1, 2022Applicant: KeyBioscience AGInventors: Kim V. Andreassen, Kim Henriksen, Nina Sonne, Morten Asser Karsdal
-
Publication number: 20220196676Abstract: The invention provides an immunological binding partner specifically reactive with a C-terminal epitope of the ?1 chain of collagen Type VIII or with an N-terminal epitope of the mature form of the ?1 chain of collagen Type VIII, and a method of immunoassay for detecting or quantitating in a sample the C-terminal epitope or the N-terminal epitope of the mature ?1 chain of collagen type VIII.Type: ApplicationFiled: February 28, 2022Publication date: June 23, 2022Applicant: Nordic Bioscience A/SInventors: Niels Ulrik Brandt Hansen, Diana Julie Oernes-Leeming, Morten Asser Karsdal
-
Publication number: 20200355687Abstract: The present invention relates to a type XVI collagen assay and its use in evaluating diseases associated with type XVI collagen, in particular colorectal cancer and ulcerative colitis, and for identifying a subgroup of patients with Crohn's disease that have (or are likely to develop) fibrostenotic strictures.Type: ApplicationFiled: October 19, 2018Publication date: November 12, 2020Inventors: Christina Jensen, Joachim Hog Mortensen, Nicholas Willumsen, Morten Asser Karsdal
-
Patent number: 10239929Abstract: Provided herein are methods for the treatment of type I diabetes, Type II diabetes, metabolic syndrome, or obesity, or of appetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test in synergistic combination with metformin. A peptide selected from sequences SEQ ID NO: 12, SEQ ID NO: 15 and SEQ ID NO: 17 are administered.Type: GrantFiled: December 4, 2017Date of Patent: March 26, 2019Assignee: KeyBioscience AGInventors: Nozer M. Mehta, William Stern, Amy M. Sturmer, Morten Asser Karsdal, Kim Henriksen
-
Publication number: 20180238903Abstract: The invention provides an immunological binding partner specifically reactive with a C-terminal epitope of the ?1 chain of collagen Type VIII or with an N-terminal epitope of the mature form of the ?1 chain of collagen Type VIII, and a method of immunoassay for detecting or quantitating in a sample the C-terminal epitope or the N-terminal epitope of the mature ?1 chain of collagen type VIII.Type: ApplicationFiled: August 16, 2016Publication date: August 23, 2018Applicant: Nordic Bioscience A/SInventors: Niels Ulrik Brandt Hansen, Diana Julie Oernes-Leeming, Morten Asser Karsdal
-
Publication number: 20180105568Abstract: Provided herein are methods for the treatment of type I diabetes, Type II diabetes, metabolic syndrome, or obesity, or of appetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test in synergistic combination with metformin. A peptide selected from sequences SEQ ID NO: 12, SEQ ID NO: 15 and SEQ ID NO: 17 are administered.Type: ApplicationFiled: December 4, 2017Publication date: April 19, 2018Applicant: KeyBioscience AGInventors: Nozer M. Mehta, William Stern, Amy M. Sturmer, Morten Asser Karsdal, Kim Henriksen
-
Patent number: 9862754Abstract: Provided herein are peptides, that in combination with metformin, are effective for the treatment of type I diabetes, Type II diabetes, metabolic syndrome, or obesity, or of appetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test in synergistic combination with metformin. The peptides are selected from sequences SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 24.Type: GrantFiled: October 1, 2016Date of Patent: January 9, 2018Assignee: KeyBioscience AGInventors: Nozer M. Mehta, William Stern, Amy M. Sturmer, Morten Asser Karsdal, Kim Henriksen
-
Publication number: 20170096467Abstract: Provided herein are peptides, that in combination with metformin, are effective for the treatment of type I diabetes, Type II diabetes, metabolic syndrome, or obesity, or of appetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test in synergistic combination with metformin. The peptides are selected from sequences SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 24.Type: ApplicationFiled: October 1, 2016Publication date: April 6, 2017Applicant: KeyBioscience AGInventors: Nozer M. Mehta, William Stern, Amy M. Sturmer, Morten Asser Karsdal, Kim Henriksen
-
Patent number: 9533022Abstract: Provided herein are methods for the treatment of type I diabetes, Type II diabetes, metabolic syndrome, or obesity, or of appetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test in synergistic combination with metformin. Treatment is effected with a combination therapy of metformin and a peptide with a sequence selected from SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 24 administered to a patient.Type: GrantFiled: February 27, 2015Date of Patent: January 3, 2017Assignee: KeyBioscience A/SInventors: Nozer M. Mehta, William Stern, Amy M. Sturmer, Morten Asser Karsdal, Kim Henriksen
-
Publication number: 20150196617Abstract: Provided herein are methods for the treatment of type I diabetes, Type II diabetes, metabolic syndrome, or obesity, or of appetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test in synergistic combination with metformin. Treatment is effected with a combination therapy of metformin and a peptide with a sequence selected from SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 24 administered to a patient.Type: ApplicationFiled: February 27, 2015Publication date: July 16, 2015Applicant: KEYBIOSCIENCE AGInventors: Nozer M. Mehta, William Stern, Amy M. Sturmer, Morten Asser Karsdal, Kim Henriksen
-
Patent number: 9006172Abstract: A peptide having a sequence selected from SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17 and SEQ ID NO:18. Said peptide used for the treatment of type I diabetes, Type II diabetes, metabolic syndrome, or obesity, or of apetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test.Type: GrantFiled: November 2, 2012Date of Patent: April 14, 2015Assignee: KeyBioscience AGInventors: Nozer M. Mehta, William Stern, Amy M. Sturmer, Morten Asser Karsdal, Kim Henriksen